Orsiro Mission 2.25/9/140Recalls & reported problems
Biotronik AG · Class 3 · Implant
All models of Orsiro Mission (49)
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 11
- Deaths reported
- 0
- Injuries reported
- 0
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 11 adverse event reports that list this exact device (DI 07640130455818), received between Jul 10, 2023 and Jun 3, 2026 — classified as 11 malfunctions.
The most frequently reported specific device problem is “Failure to Advance” (10 reports).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Reports received per month
Most reported problems
Device problems
- Failure to Advance10
- Device Dislodged or Dislocated2
Patient problems
- No Clinical Signs, Symptoms or Conditions11
Recent adverse event reports
The 11 most recent of 11 reports, in the reporter's own words as published by the FDA.
MalfunctionJun 3, 2026Failure to Advance
THE ORSIRO MISSION DRUG-ELUTING STENT SYSTEM WAS SELECTED FOR TREATMENT OF AN UNSPECIFIED LESION IN A SEGMENT OF THE DISTAL LAD. A PRE-DILATION OF THE LESION WAS PERFORMED. THE AFFECTED DEVICE WAS INTRODUCED INTO THE PATIENT'S BODY BUT COULD NOT CROSS THE LESION.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 25373561 ↗MalfunctionMay 5, 2026Failure to Advance
THE ORSIRO MISSION DRUG-ELUTING STENT SYSTEM WAS SELECTED FOR TREATMENT OF A MODERATELY CALCIFIED LESION (80 % STENOSIS DEGREE) IN A SEVERELY TORTUOUS SEGMENT OF THE MEDIAL LCX. A PRE-DILATION OF THE LESION WAS PERFORMED. THE AFFECTED DEVICE WAS INTRODUCED INTO THE PATIENT'S BODY BUT COULD NOT CROSS THE LESION.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 25080471 ↗MalfunctionApr 10, 2026Failure to Advance
THE ORSIRO MISSION DRUG-ELUTING STENT SYSTEM WAS SELECTED FOR TREATMENT OF A LESION IN A SEGMENT OF THE PROXIMAL TO MEDIAL BIFURCATION TO THE D1. IT IS UNKNOWN IF A PRE-DILATION OF THE LESION WAS PERFORMED. THE AFFECTED DEVICE WAS INTRODUCED INTO THE PATIENT'S BODY BUT COULD NOT CROSS THE LESION
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 24838226 ↗MalfunctionMar 17, 2026Failure to Advance
THE ORSIRO MISSION DRUG-ELUTING STENT SYSTEM WAS SELECTED FOR TREATMENT OF A LESION IN A MODERATELY CALCIFIED LESION (95 % STENOSIS DEGREE) IN A MILDLY TORTUOUS SEGMENT OF THE OSTIAL OM1. A PRE-DILATION OF THE LESION WAS PERFORMED. THE AFFECTED DEVICE WAS INTRODUCED INTO THE PATIENT'S BODY BUT COULD NOT CROSS THE LESION.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 24615216 ↗MalfunctionMar 17, 2026Failure to Advance
THE ORSIRO MISSION DRUG-ELUTING STENT SYSTEM WAS SELECTED FOR TREATMENT OF A MODERATELY CALCIFIED LESION IN A SEGMENT OF THE PROXIMAL LCX. A PRE-DILATION OF THE LESION WAS NOT PERFORMED. THE AFFECTED DEVICE WAS INTRODUCED INTO THE PATIENT'S BODY BUT COULD NOT CROSS THE LESION.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 24615215 ↗MalfunctionFeb 27, 2026Failure to Advance
THE ORSIRO MISSION DRUG-ELUTING STENT SYSTEM WAS SELECTED FOR TREATMENT OF A LESION IN AN UNKNOWN TARGET VESSEL. THE AFFECTED DEVICE WAS INTRODUCED INTO THE PATIENT'S BODY BUT COULD NOT CROSS THE LESION.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 24469263 ↗MalfunctionFeb 4, 2026Failure to Advance
THE ORSIRO MISSION DRUG-ELUTING STENT SYSTEM WAS SELECTED FOR TREATMENT OF A MILDLY CALCIFIED LESION (99 % STENOSIS DEGREE) IN A MILDLY TORTUOUS SEGMENT OF THE DISTAL RCA. A PRE-DILATION OF THE LESION WAS PERFORMED. THE AFFECTED DEVICE WAS INTRODUCED INTO THE PATIENT'S BODY BUT COULD NOT CROSS THE LESION. THE COMPLAINT DEVICE WAS NOT RETURNED FROM THE HOSPITAL.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 24256791 ↗MalfunctionFeb 3, 2026Failure to Advance
THE ORSIRO MISSION DRUG-ELUTING STENT SYSTEM WAS SELECTED FOR TREATMENT OF A MODERATELY CALCIFIED LESION (80 % STENOSIS DEGREE) IN A MILDLY TORTUOUS PART OF THE DISTAL RCA. AFTER PRE-DILATION OF THE LESION WITH A 2.0 X 15 MM BALLOON, THE AFFECTED ORSIRO MISSION WAS INTRODUCED INTO THE PATIENT'S BODY BUT WAS UNABLE TO CROSS THE LESION. EVENTUALLY, AN 2.0 X 12 MM STENT WAS SUCCESSFULLY IMPLANTED.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 24243122 ↗MalfunctionNov 28, 2025Failure to Advance; Failure to Advance
THE ORSIRO MISSION DRUG-ELUTING STENT SYSTEM WAS SELECTED FOR TREATMENT OF A MODERATELY TO SEVERELY CALCIFIED LESION (90% STENOSIS DEGREE) IN A MILDLY TORTUOUS PART OF THE MID TO DISTAL LAD. IT WAS REPORTED THAT THE STENT COULD NOT CROSS THE LESION.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 23669704 ↗MalfunctionJul 24, 2024Device Dislodged or Dislocated; Device Dislodged or Dislocated
AN ORSIRO MISSION DRUG-ELUTING STENT EMBOLIZED IN A SEVERELY CALCIFIED AND TORTUOUS DISTAL LCX. THE PATIENT WAS FLAILING THROUGHOUT THE CASE, WHICH COMPLICATED MATTERS AS WELL. IT IS BELIEVED THAT THE DOCTOR WAS ABLE TO BALLOON EMBOLIZE THE STENT INTO THE VESSEL WALL, BUT IT COULD NOT BE CONFIRMED BASED ON LIMITED STENT VISIBILITY. STENT CATHETER WAS DISPOSED IN THE HEAT OF A DIFFICULT CASE, SO IT IS NOT AVAILABLE FOR INSPECTION. AFTER ADDITIONAL CORRESPONDENCE WITH THE LOCAL STAFF, IT WAS CLARIFIED THAT THERE WERE THREE 90 PERCENT LESIONS WHICH HAD ALREADY BEEN BALLOONED AND STENTED, EXCEPT FOR THE DISTAL SEGMENT. WHEN TRYING TO DELIVER THE SMALLEST/SHORTEST STENT TO THE DISTAL LOCATION, THE SYSTEM WAS STUCK INSIDE THE PROXIMAL STENTS AND THEN DISLODGED DURING THE RETRIEVAL.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 19817697 ↗MalfunctionJul 10, 2023Failure to Advance; Device Dislodged or Dislocated; Failure to Advance; Device Dislodged or Dislocated
AN ORSIRO MISSION DRUG-ELUTING STENT SYSTEM WAS SELECTED FOR TREATMENT OF A PREDILATED LESION IN A MILDLY TORTUOUS MID-SECTION OF THE CX. AFTER UNSUCCESSFUL ATTEMPT TO CROSS THE LESION, THE DEVICE WAS WITHDRAWN INTO THE GUIDE, AND DURING REMOVAL THE STENT WAS STRIPPED OFF IN THE CO-PILOT. THE STENT WAS REMOVED FROM THE CO-PILOT.
Patient problems: No Clinical Signs, Symptoms or Conditions
MAUDE report 17291650 ↗
Other Coronary drug-eluting stent devices
- SYNERGY™ H7493926038300Boston Scientific Corporation · Coronary drug-eluting stent8 deaths124 reports
- SYNERGY™ H7493926016300Boston Scientific Corporation · Coronary drug-eluting stent7 deaths106 reports
- SYNERGY™ H7493926020300Boston Scientific Corporation · Coronary drug-eluting stent9 deaths90 reports
- SYNERGY™ H7493926016250Boston Scientific Corporation · Coronary drug-eluting stent6 deaths82 reports
- XIENCE Sierra™ 1550350-33Abbott Vascular Inc. · Coronary drug-eluting stent1 recall32 reports
- Resolute Onyx™ RONYX30022UXMedtronic, Inc. · Coronary drug-eluting stent6 deaths76 reports
- SYNERGY™ H7493926024300Boston Scientific Corporation · Coronary drug-eluting stent3 deaths75 reports
- Resolute Onyx™ RONYX30015UXMedtronic, Inc. · Coronary drug-eluting stent3 deaths73 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page